The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1480
ISSUE1480
October 26, 2015
Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI
October 26, 2015 (Issue: 1480)
The FDA has approved cangrelor (Kengreal – The
Medicines Company), an IV P2Y12 platelet inhibitor,
as an adjunct to percutaneous coronary intervention
(PCI) in patients who have not been pretreated with a
P2Y12 inhibitor and are not being given...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.